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Background: The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and
prednisone (ACVBP) in comparison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy
for young patients with localized diffuse large B-cell lymphoma (DLBCL) was previously demonstrated. We report the
results of a trial which evaluates the role of rituximab combined with ACVBP (R-ACVBP) in these patients.
Patients and methods: Untreated patients younger than 66 years with stage I or II DLBCL and no adverse
prognostic factors of the age-adjusted International Prognostic Index were randomly assigned to receive three cycles of
ACVBP plus sequential consolidation with or without the addition of four infusions of rituximab.
Results: A total of 223 patients were randomly allocated to the study, 110 in the R-ACVBP group and 113 in the
ACVBP group. After a median follow-up of 43 months, our 3-year estimate of event-free survival was 93% in the
R-ACVBP group and 82% in the ACVBP group (P = 0.0487). Three-year estimate of progression-free survival was
increased in the R-ACVBP group (95% versus 83%, P = 0.0205). Overall survival did not differ between the two groups
with a 3-year estimates of 98% and 97%, respectively (P = 0.686).
Conclusion: In young patients with low-risk localized DLBCL, rituximab combined with three cycles of ACVBP plus
consolidation is signiﬁcantly superior to ACVBP plus consolidation alone.
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introduction
In the past, patients with limited-stage aggressive lymphomas
were treated with radiation therapy (RT) alone, but a minority
were cured [1]. Then, a brief course of chemotherapy followed
by RT was shown to improve the outcome of these patients [2],
but other authors suggested that chemotherapy alone could
also cure some of them [3]. In the nineties, the Southwest
Oncology Group (SWOG) 8736 trial demonstrated the
superiority of three cycles of chemotherapy with
cyclophosphamide, doxorubicin, vincristin and prednisone
(CHOP) followed by involved-ﬁeld RT compared with eight
cycles of CHOP alone [4], and for many years, abbreviated
chemotherapy + RT was considered as the standard for the
treatment of limited-stage diffuse large B-cell lymphoma
(DLBCL). This contention was subsequently challenged by the
LNH 93-01 trial of the Groupe d’Etude des Lymphomes de
l’Adulte (GELA), which showed that young patients treated for
localized low-risk DLBCL with a dose-intense regimen
combining doxorubicin, cyclophosphamide, vindesine,
bleomycin and prednisone (ACVBP) plus consolidation had a
longer event-free survival (EFS) and overall survival (OS) than
patients treated with three cycles of CHOP plus RT [5].
The controversy concerning the best treatment in
limited-stage DLBCL is far to be resolved, especially as
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chemo-immunotherapy has become the new standard [6, 7].
Following the results observed in the LNH 93-01 study [5], the
GELA launched the prospective phase III randomized LNH
03-1B trial to explore whether the addition of four doses of
rituximab to three cycles of ACVBP could further improve the
outcome of low-risk patients without any adverse prognostic
factor of the age-adjusted International Prognostic Index
(aa-IPI 0).
methods
participants and randomization
Between December 2003 and March 2008, we did a phase III multicenter
randomized trial in 43 centers of GELA in France, Belgium and
Switzerland (see supplementary Appendix, available at Annals of Oncology
online). Patients were eligible if they were aged from 18 to 65 years and
had untreated DLBCL diagnosed in accordance with the World Health
Organization (WHO) classiﬁcation [8]. We required that patients had no
adverse prognostic factor of the aa-IPI [9]. Patients were not eligible if they
had central nervous system (CNS) involvement by lymphoma;
contraindication to any drug included in the chemotherapy regimens; any
serious, active disease (according to the investigator’s decision); abnormal
renal or hepatic function or poor bone marrow reserve unless these
abnormalities were related to the lymphoma; any history of treated or non-
treated indolent lymphoma.
Patients had to provide written informed consent before registration.
Our study complied with all provisions of the Declaration of Helsinki and
its current amendments. The protocol and informed consent forms were
approved by the local and national institutional review boards in each
participating country. Our trial was not masked. We randomly assigned
patients in a one-to-one ratio to receive ACVBP or ACVBP plus rituximab
(R-ACVBP). Treatment allocation was stratiﬁed by center and by the
presence or absence of a bulky disease. GELA, via GELARC, was involved
in the random assignment procedure, distribution and collection of case
report forms, data entry and validation, coordination of monitoring
procedures, elaboration and mailing of queries, reporting of serious adverse
events (SAEs), coordination of histological review, statistical analysis and
production of the report.
procedures
The extent of the disease was assessed by physical examination; relevant
laboratory tests; computed tomography of the chest, abdomen and pelvis;
bone marrow biopsy; and other investigational procedures, depending on
clinical symptoms. 18Fluorodeoxyglucose–positron emission tomography
(PET) was not mandatory for staging or assessment of response to
treatment. Stage was deﬁned in accordance with the Ann Arbor
classiﬁcation. Tumor measurements were assessed by treating physician or
local radiologist. We deﬁned bulky disease as any mass ≥10 cm at the
maximal diameter.
A central review was conducted by at least two pathologists from the
GELA, without knowledge of the patient outcome, to conﬁrm the diagnosis
of CD20-positive DLBCL. Tumors were classiﬁed in accordance with the
WHO classiﬁcation [8].
Chemotherapy regimen consisted of an induction phase of three cycles
of ACVBP given every 2 weeks with a subsequent consolidation phase
containing different treatment sequences, as previously described [5]. The
administration of granulocyte colony-stimulating factors (G-CSFs) was at
the discretion of each investigator. Prophylaxis of CNS relapses with
intrathecal chemotherapy was not administered. In the R-ACVBP group,
patients received four doses of rituximab (375 mg per square meter) on
days 1, 15, 29 and 43 of the regimen. Radiotherapy was not permitted in
the protocol.
Tumor responses were assessed by the local investigator after three
cycles and at the end of treatment in each group. Responses were classiﬁed
as complete response (CR), unconﬁrmed complete response (CRu) or
partial response (PR), and disease state was identiﬁed as stable or
progressive disease, based on the International Workshop 1999 criteria [10].
All AEs reported by the patient or observed by the investigator were
collected from the case report form and was graded according to the
National Cancer Institute Common Toxicity Criteria grading system
(Version 3.0). All grade 3 and 4 events and grade 2 infections were
recorded in detail.
statistical analysis
We used EFS, our primary end point, to assess sample size. Given a 2-year
rate of EFS of 83% in the group assigned to ACVBP in the LNH 93–01
trial and to detect an improvement of 10% (null hypothesis: 60%, alternate
hypothesis: 70%), it was calculated that 400 patients would be required over
a period of 4 years and followed for a minimum of 1 year to provide the
trial with 90% power at an overall 5% signiﬁcance level. An interim analysis
was planned after the inclusion of 200 patients. The trial was opened in
December 2003. Because of a slow rate of inclusions, the data and safety
monitoring committee recommended to close the study in March 2008, at
which time 223 patients had been randomly allocated to the study.
We measured EFS from the date of randomization to the date of the ﬁrst
event. We deﬁned events as death from any cause, disease progression
during or after treatment, relapse for complete responders and
unconﬁrmed complete responders and implementation of any lymphoma
treatment not stipulated by the protocol, including radiotherapy. Secondary
end points were response to treatment, progression-free survival, disease-
free survival, OS, safety and rate of CNS progression or relapse.
Survival curves were computed by the Kaplan–Meier method and
compared by the log-rank test. We calculated hazard ratios (HR) and 95%
conﬁdence intervals (CI) with the use of a Cox proportional-hazards
analysis. Univariate analyses assessed the effect of pretreatment-speciﬁed
factors (age, sex, stage I/II, presence or absence of extranodal site or bulky
disease, B symptoms, beta2-microglobulin level, serum albumin level) on
PFS and OS. Interaction between these factors and treatment arms was also
evaluated with the Cox analysis.
Analyses of efﬁcacy and safety were of the intention-to-treat population.
One patient who withdrew consent before any procedure was excluded
from the population. All P-values are two-sided. Statistical analyses were
carried out with the SAS 9.1.3 software (SAS Institute, Cary, NC) by the
GELARC statistical ofﬁce.
This trial is registered with ClinicalTrials.gov, number NCT00140595.
results
patient characteristics
We enrolled 223 patients in the trial, of which 222 received at
least one dose of planned treatment; 112 were assigned to the
ACVBP and 110 to the R-ACVBP arm. The main
characteristics did not differ between the treatment groups
(Table 1). The pathological central review was carried out in
93% of the patients and conﬁrmed DLBCL in 95% of them.
Median age was 49 years (range 18 to 65 years), and 10% of
the patients were older than 60. Stage I disease was diagnosed
in 63% of the patients. Bulky disease was present in 4% of the
cases. Forty-ﬁve percent of the patients had primary extranodal
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disease (Table 1). At the data cut-off point, 1 April 2009, the
median follow-up was 43 months.
treatment and response
Ninety-nine percent of the patients in both arms received the
three induction cycles. G-CSFs were administered to 80%, 89%
and 87% of the patients during the ﬁrst, second and third
induction cycles, respectively, without any difference between
the two groups. At the end of the treatment, CR/CRu was
observed in 105 (94%) patients treated with ACVBP
chemotherapy and in 107 (97%) patients who received R-
ACVBP (Table 2). Progression occurred under treatment in
three and in one patient treated with ACVBP and R-ACVBP,
respectively.
safety
The most common toxic effects were represented by
hematological toxicity in both groups (Table 3). A total of 209
Table 1. Patient characteristics
Characteristics ACVBP R-ACVBP
Number of patients Percentage Number of patients Percentage
Total number of patients 112 110
Median age, years 48 50.5
Age 60 to 65 years 10 9 13 12
Male sex 68 61 71 65
Stage
I 70 63 70 64
II 41 37 39 35
III–IVa 1 <1 1 1
Lactate dehydrogenase level
Normal 111 99 110 100
Elevateda 1 1
Performance status
0–1 112 100 110 100
aa-IPI
0 110 98 109 99
1a 2 2 1 1
Bulky disease at randomization 8 7 2 2
Presence of B symptoms 25 22 16 15
Β2-microglobulin >3 mg/l 5 5 2 2
Extranodal involvement 44 39 56 51
Organ involved
Waldeyer’s ring and sinus 19 17 17 <16
Stomach 6 5 9 8
Intestine 3 <3 3 3
Parotide 4 <4 6 5
Thyroid 1 1 3 3
Bone 2 2 4 <4
Gonad 3 <3 3 3
Breast 2 2 2 2
Skin or subcutaneous site 2 2 3 3
Otherb 2 2 6 5
Histological ﬁndingsc
Centrally reviewed 106 94 102 93
DLBCL 98 93 97 95
No DLBCL 6 5 4 <4
Follicular lymphoma grade 1–3A 4 <4 1 1
Follicular lymphoma grade 3B 1 1
Marginal zone lymphoma 1 1
Nodular lymphocyte-predominant Hodgkin 2 2
Myeloma 1 1
Unclassiﬁed aggressive lymphoma 2 2
Insufﬁcient sample 1 1
aSome included patients had an aa-IPI >0 at data review.
bOther categories include: spleen, bladder, gingival mucosa, bronchia, vagina and uterus cervix.
cWHO classiﬁcation was used.
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AEs in the ACVBP arm and 183 AEs in the R-ACVBP group
were reported, concerning 79 (71%) and 75 (68%) patients,
respectively. Forty-seven SAEs were declared in the ACVBP
group and 50 in the R-ACVBP arm, in 30 patients (27%) in
each group. There were mainly related to infections (13 SAEs
in the ACVBP group and 19 SAEs in the R-ACVBP group).
There was one treatment-related death in the R-ACVBP arm,
secondary to a pneumocystis jiroveci pneumonia.
outcome
Twenty-eight events were observed, 19 in the ACVBP arm
(17% of the patients) and 9 in the R-ACVBP arm (8% of the
patients). EFS differed signiﬁcantly between the groups
(P = 0.0487; HR 0.46) with a 3-year estimate of 82% (95% CI:
73% to 88%) in the ACVBP group and 93% (95% CI: 87% to
97%) in the R-ACVBP group (Figure 1).
There were 23 relapses or progressions, 17 in the ACVBP
arm and 6 in the R-ACVBP arm. All progressions occurred
during the follow-up period, except for three patients in the
ACVBP and for one in the R-ACVBP group who progressed
during treatment. Progression in the initial site was observed in
15 out of 17 patients (88%) who relapsed after ACVBP and in
4 out of 6 patients (67%) who relapsed after R-ACVBP. Three
of the 10 patients presenting bulky disease progressed, 2 after
ACVBP and 1 after R-ACVBP. None of the patient developed
CNS progression in this trial. PFS was signiﬁcantly different
(P = 0.0205; HR 0.37) with a 3-year estimates of 83% (95% CI:
74% to 89%) in the ACVBP group and 95% (95% CI: 89% to
98%) in the R-ACVBP group (Figure 2). R-ACVBP treatment
reduced the risk of experiencing a progression or death by 63%
compared with ACVBP (P = 0.0261; HR 0.371). In a
multivariate analysis, PFS was independently affected by the
treatment with chemo-immunotherapy (P = 0.0302; HR 0.324;
95% CI: 0.117 to 0.898) and by a β2-microglobulin level ≥3
mg/l (P = 0.0164; HR 5.256; 95% CI: 1.355 to 20.382).
Fifteen of the 17 patients (88%) who progressed after
ACVBP received salvage chemo-immunotherapy. Twelve
Table 2. Response to treatmenta
Characteristics ACVBP (n = 112) R-ACVBP (n = 110)
Number of
patients
Percentage Number of
patients
Percentage
CR or CRu 105 94 107 97
PR 2 2 0 0
Primary failure 3 3 1 1
Death 0 0 1 1
Not evaluated 2 2 1 1
aResponse was assessed 1 month after the completion of the treatment in
212 assessable patients.
Table 3. Toxic effects according to treatment groups (safety population)
ACVBP (n = 112) R-ACVBP (n = 110)
Any
grade
Grade
≥3
Any
grade
Grade
≥3
Number of patients (%) with an event in
at least one cycle
Anemia 99 (89) 23 (21) 94 (85) 21 (19)
Neutropenia 88 (79) 81 (73) 90 (81) 84 (76)
Thrombocytopenia 76 (68) 14 (13) 70 (63) 17 (15)
Febrile neutropenia 49 (44) 49 (44) 39 (35) 39 (35)
Infection in neutropenic
period
17 (15) 10 (9) 17 (15) 15 (14)
Infection out of neutropenic
period
11 (10) 2 (2) 17 (15) 4 (4)
Vomiting 39 (35) 3 (3) 34 (31) 1 (1)
Diarrhea 18 (16) 0 (0) 14 (13) 0 (0)
Mucositis 62 (56) 21 (19) 60 (54) 12 (11)
Cardiac toxicity 4 (4) 1 (1) 5 (5) 0 (0)
Coagulation and/or vascular
toxicity
3 (3) 1 (1) 6 (6) 2 (2)
Lung toxicity 13 (12) 1 (1) 11 (10) 3 (3)
Aminotransferase elevation 36 (32) 2 (2) 28 (25) 0 (0)
Creatinine elevation 6 (5) 0 (0) 6 (5) 0 (0)
Neurologic toxicity 24 (22) 3 (3) 20 (18) 2 (2)
Skin toxicity 28 (25) 0 (0) 17 (15) 1 (1)
Other 62 (56) 11 (10) 64 (58) 8 (7)
Figure 1. Event-free survival among patients assigned to chemotherapy
with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone
(ACVBP) regimen alone or to ACVBP plus rituximab.
Figure 2. Progression-free survival among patients assigned to
chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin
and prednisone (ACVBP) regimen alone or to ACVBP plus rituximab.
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(71%) achieved a CR, one (6%) a PR, three (18%) progressed
and one patient was not evaluated for response. Eleven (65%)
of them received an intensiﬁed regimen with autologous stem
cell transplant. All the six patients who progressed following R-
ACVBP received second-line chemo-immunotherapy, three
(50%) achieving a CR and two (33%) a PR. The last patients
did not respond to the salvage treatment. Four of these six
patients (67%) went to autologous stem cell transplantation.
There were eight deaths at the time of ﬁnal analysis, four in
each arm. OS did not signiﬁcantly differ between the two
groups (P = 0.686; HR 1.36) with a 3-year estimates of 97%
(95% CI: 90% to 99%) in the ACVBP group and 98% (95% CI:
92% to 100%) in the R-ACVBP group (Figure 3). The causes of
deaths could be documented in all patients except for one in
the R-ACVBP arm. Four deaths were related to lymphoma
progression (three after ACVBP and one after R-ACVBP). One
patient in the R-ACVBP group died because of toxicity of
study treatment (pneumocystic jiroveci pneumonia), one
patient in each arm died for a reason unrelated to lymphoma
or treatment.
discussion
The present randomized trial planned initially to recruit over 4
years 400 patients younger than 66 years of age, but a slow rate
of inclusions resulted in a premature closure of the study. This
was probably due to the increasing reluctance of the
investigators during this period of time to not administer
rituximab even to these low-risk patients. However, a longer
follow-up allowed this study to keep its 90% power and the
expected level of signiﬁcance despite a smaller patient
population. In total, 222 patients were enrolled and we could
demonstrate that the addition of rituximab to three cycles of
ACVBP plus consolidation improves signiﬁcantly the outcome
of patients with localized low-risk DLBCL. We observed with a
median follow-up of nearly 4 years a 3-year EFS of 93% for
patients receiving chemo-immunotherapy compared with 82%
for those treated with ACVBP. At this time, no difference in
OS is observed, with 98% and 97% of the patients being alive
in the respective groups.
The best treatment for localized aggressive non-Hodgkin
lymphoma has been a topic of long debate in the pre-
rituximab area. The SWOG 8736 randomized trial published
by Miller et al. [4] demonstrated a longer PFS and OS
following a treatment combining three cycles of CHOP with
involved-ﬁeld RT, compared with eight cycles of CHOP alone.
However, long-term updated results of the study no longer
demonstrated differences in survival because of an excess of
late relapses in patients treated with combined chemo-
radiotherapy [11]. Horning et al. [12] reported another trial
conducted by the ECOG which randomly compared
consolidative RT after eight cycles of CHOP in patients with
limited stage aggressive lymphoma. The combined approach
marginally improved the EFS but did not signiﬁcantly affect
the survival. Conversely, two randomized trials conducted by
the GELA failed to show any beneﬁt of consolidative RT after
chemotherapy in this setting. The LNH 93-4 trial carried out
in elderly patients treated for a low-risk localized aggressive
lymphoma did not show any superiority of four cycles of
CHOP plus RT over four cycles of CHOP alone [13]. In a
younger population, similar to those of the present trial, the
LNH93-1 trial compared three cycles of CHOP followed by RT
with ACVBP and sequential consolidation without RT.
Signiﬁcantly longer EFS and OS were demonstrated for
patients treated with ACVBP regimen, independently of the
tumor stage and of the presence of bulky disease [5]. The
present LNH 03-1B trial conﬁrms the results obtained with
ACVBP in the LNH 93-1 study and demonstrates an
additional improvement of EFS with the addition of rituximab.
Along these last years, the dramatic improvement observed
with the addition of rituximab to chemotherapy has called
further into question the role of consolidative RT in localized
DLBCL. In the MabThera International Trial (MInT), patients
with favorable risk-localized DLBCL received six cycles of
CHOP-like chemotherapy with or without rituximab and no
radiation (except to bulky disease). When treated with
rituximab-containing regimen, the subgroup of patients with
no risk factor according to the IPI score had a 3-year PFS of
89% and 78% for non-bulky and bulky disease, respectively [7].
Obviously, these two trials are not fully comparable, and
notably the impact of tumor bulk cannot be assessed in our
current trial in which <5% of the patients presented bulky
disease. Moreover, our study might include a larger proportion
of patients with more favorable characteristics, stage I without
bulky disease being not included in the MInT trial. In a phase
II study carried out by the SWOG, patients with early-stage
DLBCL were treated with three cycles of R-CHOP followed by
involved-ﬁeld RT. Most patients had one IPI risk factor, and
the 88% PFS observed at 4 years was better compared with
historical controls that included patients treated with chemo-
radiotherapy without rituximab [14]. Another pilot study
including patients with primary mediastinal B-cell lymphoma
showed that rituximab combined with dose-adjusted EPOCH
regimen provides 3-year EFS of 94% without consolidative RT
[15]. Furthermore, Sehn et al. [16] demonstrated in a
retrospective analysis that patients presenting a DLBCL
without any adverse prognostic factors of the IPI score and
treated with R-CHOP had an excellent outcome with a 4-year
PFS of 94%. Finally, a randomized trial carried out in young
Figure 3. Overall survival among patients assigned to chemotherapy with
doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone
(ACVBP) regimen alone or to ACVBP plus rituximab.
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patients treated for DLBCL and an age-adjusted IPI of 1 was
recently published and demonstrated a superiority of R-
ACVBP over R-CHOP in term of EFS and OS [17].
It is remarkable that the 10% EFS improvement observed in
the R-ACVBP arm in our study was obtained with four
infusions of rituximab only. While the current standard of
treatment for DLBCL usually consists in six to eight cycles of
chemotherapy combined with eight doses of rituximab, the
optimal dose and schedule of rituximab administration is not
fully well established. Pfreundschuh et al. [18] have suggested
that a rituximab dose-dense regimen could increase the
treatment efﬁciency and improve the outcome of patients with
poor-prognosis DLBCL, compared with historical controls
receiving standard R-CHOP. Interestingly, our results suggest
that the outcome of patients with low-risk disease may be
improved by only four doses of rituximab. Of course, we
cannot speculate if the results would have been the same using
eight infusions of rituximab.
In conclusion, our study demonstrates that the outcome of
low-risk patients treated for localized DLBCL can be improved
by the addition of only four doses of rituximab to ACVBP. The
hematological toxicity, while manageable, is higher compared
with the one observed following R-CHOP, and we assume that
a signiﬁcant proportion of our patients might have been cured
with this latter regimen. Finally, questions persist today
regarding the best treatment of localized low-risk DLBCL. The
majority of these patients are currently cured with rituximab-
containing chemotherapy regimens, and whether some of them
could beneﬁt safely from a decreased treatment intensity
remains to be determined. Only randomized trials will be able
to answer this question, such as the FLYER trial initiated by
the German group which compares six to four cycles of R-
CHOP in the subset of DLBCL patients with very good
prognosis. Moreover, it could be anticipated that PET-CT may
represent an important tool to tailor more precisely the best
treatment in this setting and to determine among this low-risk
population which patients could safely beneﬁt from a decrease
in the treatment intensity. In that respect, the GELA has
recently launched a randomized trial to evaluate the feasibility
to adapt the treatment according the early response evaluated
by PET-CT in patients with low-risk DLBCL treated with R-
CHOP21.
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